Back to today’s briefing

Story perspectives

Evoke Pharma Acquired by QOL Medical at 139.7% Premium

11/5/2025

47 7

Summary

Story summary

Evoke Pharma of Solana Beach, California, will be acquired by QOL Medical for $11 per share, a 139.7% premium over its recent close, with both boards unanimously approving and a closing expected by the end of 2025.
Evoke's flagship product, GIMOTI, is the first FDA-approved nasal spray for diabetic gastroparesis with rapid symptom relief.
The move broadens GIMOTI's reach and leverages QOL Medical's gastrointestinal expertise.

1 of 1

Story summary

Evoke Pharma of Solana Beach, California, will be acquired by QOL Medical for $11 per share, a 139.7% premium over its recent close, with both boards unanimously approving and a closing expected by the end of 2025.
Evoke's flagship product, GIMOTI, is the first FDA-approved nasal spray for diabetic gastroparesis with rapid symptom relief.
The move broadens GIMOTI's reach and leverages QOL Medical's gastrointestinal expertise.